These emerging therapies , Tirzepatide , represent a remarkable advancement in treating obesity and possibly related conditions . These drugs are categorized as GLP-1 receptor agonists , signifying https://gregoryvmia557053.qowap.com/100438180/semaglutide-a-deep-dive-into-incretin-copyright